Co-Diagnostics Inc (CODX)

[Opti Mist]

Correction printed.

Co-Diagnostics Q2 revenues $24M on continued demand for COVID-19 tests
Aug. 13, 2020 4:46 PM ET| About: Co-Diagnostics, Inc. (CODX)|By: Douglas W. House, SA News Editor
Co-Diagnostics (NASDAQ:CODX) Q2 results:

Revenue: $24.0M (+999%). Revenue largely comprised on COVID-19 test sales. 2019 sales of $61.6K were driven by the sale of two MDx devices to mosquito abatement districts and service revenue related to the design of custom tests for a large agricultural company.

Net income: $12.6M (+999%); EPS: $0.43 (+637.5%).

Cash consumption (6 mo.): ($0.3M) (+88.9%).

Final stages of principal design work and verification of multiplex panel for influenza A&B and COVID-19. Deployment planned this quarter.

Shares down 16% after hours.

Co-Diagnostics EPS misses by $0.16, misses on revenue

https://seekingalpha.com/news/3605440-co-diagnostics-q2-revenues-24m-on-continued-demand-for-covidminus-19-tests?utm_medium=email&utm_source=seeking_alpha&mail_subject=correction-codx-co-diagnostics-q2-revenues-24m-on-continued-demand-for-covid-19-tests&utm_campaign=rta-stock-news&utm_content=link-3

Opti